Drug Trial Radar · NCT07098364
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
33
Planned (sponsor's estimate)
Start
Dec 27, 2025
Primary completion
Oct 4, 2030
Study completion Oct 4, 2043
Sponsor
- Lead sponsor
- Fred Hutchinson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Simcha Therapeutics
- First posted
- Aug 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial tests the safety, side effects, and best dose/regimen of ST-067 in combination with CD19-directed chimeric antigen receptor (CAR) T-cell therapy (liso-cel) and how well it works in treating patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (recurrent) or LBCL that has not responded to previous treatment (refractory). ST-067 is an engineered variant of the human cytokine interleukin-18 that may help the immune system kill cancer cells. Lisocabtagene maraleucel (liso-cel) is an autologous CAR T-cell therapy prepared using the person's own immune system (a group of cells, tissues, and organs that protect the body from attack by bacteria, viruses, and cancer cells) to fight the cancer. Giving ST-067 in combination with liso-cel may better treat patients with relapsed/refractory LBCL.
Conditions
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High-Grade B-Cell Lymphoma
- Recurrent Indolent B-Cell Non-Hodgkin Lymphoma
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Grade 3b Follicular Lymphoma
- Refractory High-Grade B-Cell Lymphoma
- Refractory Indolent B-Cell Non-Hodgkin Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
Interventions
VevoctadekinBiological
Given SC
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Computed TomographyProcedure
Undergo CT
Echocardiography TestProcedure
Undergo ECHO
LeukapheresisProcedure
Undergo leukapheresis
Lisocabtagene MaraleucelBiological
Given IV
Lumbar PunctureProcedure
Undergo lumbar puncture
Lymphodepletion TherapyProcedure
Undergo lymphodepletion chemotherapy
Multigated Acquisition ScanProcedure
Undergo MUGA
Positron Emission TomographyProcedure
Undergo PET scan
X-Ray ImagingProcedure
Undergo x-ray
Biospecimen CollectionProcedure
Undergo blood and CSF sample collection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: Up to 4 years
- Dose limiting toxicities (DLT)Time frame: Up to 21 days following the first vevoctadekin (ST-067) dose
- Optimal biological regimenTime frame: Up to 4 years
- Complete response (CR) rateTime frame: At 3 months after liso-cel infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.